AC Immune receives a "Buy" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056 in early Parkinson's Disease. AC Immune is advancing ACI-7104.056, with upcoming FDA discussions to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback